anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cysteamine has not been tested for its carcinogenic potential in long-term animal studies.

PROCYSBI was not mutagenic in the Ames test. It produced a negative response in an in-vitro sister chromatid exchange assay in human lymphocytes, but a positive response in a similar assay in hamster ovarian cells.

Repeat breeding reproduction studies were conducted in male and female rats. Cysteamine was found to have no effect on fertility and reproductive performance at an oral dose of 75 mg/kg per day (450 mg/m2 per day, 0.4 times the recommended human dose based on body surface area). At an oral dose of 375 mg/kg per day (2250 mg/m2 per day, 1.7 times the recommended human maintenance dose based on body surface area), it reduced the fertility of the adult rats and the survival of their offspring.
The invention provides a method of reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (.rho. m) and the total number of amino acid residues (r) wherein 3.rho. m is the largest number that is less than or equal to r + 1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (.rho. t) wherein 2a is the largest number that is less than or equal to .rho. t + 1, except that when a is 1, .rho. t may also be 1.
PURPOSE:To provide an aq. molding material which can release various chemicals contained in the material into water at a constant rate by using a specific fatty acid ester of a polyoxyalkylene glycerin ether as a main component. CONSTITUTION:An aq. molding material having an m.p. of 40-100 deg.C and a melt viscosity of 80-10000cp at a temp. 10 deg.C higher than the m.p. is prepd. by incorporating, as main components, one or more fatty acid esters of polyoxyalkylene glycerin esters of the formula (wherein R1 is H, 1-8C alkyl or 8-24C acyl; R2 is H or 8-24C acyl; l is 20-700; m is 0 or 20-200, and l+m is 20-700; and r and s are each 0 or 1-10). The molding material can be molded into a given shape with chemicals such as perfumes, detergents, etc., contained therein, and can release said chemicals into water at a constant rate.
Azacitidine 75 mg/m2 IV on days 1-5 of each 28 day cycle. Patients that do not respond after two cycles will have the dose increased to 100 mg/m2. Patients who achieve a CR will receive 3 additional 28 day cycles and then begin treatment on days 1-5 of a 56 day cycle. Individuals who demonstrate a loss of response will resume 28 day cycles.
Veterans, National Guardsmen, \& Reservists with post-traumatic stress disorder (PTSD) and problems with addiction need a wider array of treatment options than what is currently available. The present project offers the promise of a complementary approach that uses computer-based interventions to augment exposure therapy for veterans with both PTSD and use alcohol, nicotine and/or other substances. If this new intervention is found to be efficacious in the present project, it would provide an alternative to standard treatment for a growing number of veterans who are at risk for lifetime problems with PTSD and addiction, but who may be unwilling to begin usual psychotherapy. This direct way of training new behavior in the clinic and extending learning into the real world is missing in treatments for many medical and psychiatric conditions. As such, the impact of this project could extend into treatment of a wide variety of other chronic conditions for which more powerful new treatments are needed. Veterans will be recruited from the Durham Veterans Affairs Medical Center (Durham VAMC) and local community.

Participants (N = 60) meeting full criteria for current diagnoses of both PTSD and at least one SUD were to be recruited through the Durham Veterans Affairs Medical Center (Durham VAMC). 100 participants were to be enrolled (sign the consent form) in order to identify 60 who meet inclusion/exclusion criteria. Actually 123 subjects signed consent and 38 subjects are considered ITT (intent to treat-met inclusion/exclusion criteria, randomized and showed to their first therapy session). Participants were randomly assigned to one of two treatment conditions-exposure therapy alone or exposure therapy + virtual reality (VR)-based exposure to cues for marijuana, cocaine, heroin, cigarette, and/or alcohol use, and (2) cellular phone-based reminders of learning (extinction reminders, or, ERs) to VR exposure. Matching between treatment groups was based on age, gender, severity of PTSD and substance use. In addition, to control for differential dropout and other changes in treatment due to cell phone use in the VR/ER condition, participants in the control condition also carried cell phones, and were randomly called three times a day via the automated server (same as the VR/ER condition). These calls were completed for assessment only, to obtain real time self-reports of substance use and cravings (without the ER). Comprehensive assessments were conducted at pre-treatment, 10 weeks (post-treatment), and at a 6-month follow-up.

The goals of this project are to examine the acceptability and feasibility of the complementary treatment and evaluate the effects of the complementary intervention on PTSD and substance use.
Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Placebo (Glucose 5%) administered 2 weeks apart. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
The invention relates to a preparation technology and a preparation method of integrated novel dosage form of cardamom soup. The cardamom soup comprises the following effective components by weight: 7 parts of clove, 11 parts of prepared liquorice, and 8 parts of nutmeg. The preparation method comprises the steps of: milling with supersonic airflow, extracting with alcohol and water, extracting with ultrasonic wave while pulverizing, decocting with water to concentrate, spray drying under condition of supersonic speed, performing nano-grinding, emulsifying under high pressure for homogenization, and preparing nanoparticles. The emphasis of the preparation technology and the production method provided by the invention is mainly laid on utilizing the advantages of nano-carrier combination technique, such as multi-synergy and multi-target. By carrying out large-scale production, the production cost can be largely decreased, the product quality can be greatly improved, and functions of targeting and sustained and controlled-release of drug prepared by the method can be increased. The prepared drug can be orally administered and externally applied and can be applied in four time periods respectively according to midnight-noon and ebb-flow doctrine and rule of human body blood flow. Film-forming agent and transdermal agent prepared by the method can be applied respectively to different parts of human body according to the midnight-noon and ebb-flow doctrine and the rule of human body blood flow, and can be absorbed directly through skin.
The present invention provides a recombinant monoclonal antibody against REG gamma protein, which comprises a heavy chain variable region and a light chain variable region. The nucleotide sequence and the amino acid sequence of the heavy chain variable region are respectively shown as SEQ ID NO. 1 and SEQ ID NO. 3, and the nucleotide sequence and the amino acid sequence of the light chain variable region are respectively shown as SEQ ID NO.2 and SEQ ID NO. 4. The invention co-transfects the light chain and heavy chain eukaryotic expression plasmid carrying recombinant antibody gene to HEK293T cell for expression and purification. Using a monoclonal antibody against the REG. gamma.C terminal region as a control antibody, the performance of the antibody of the present invention was evaluated by WesternBlot, cellular immunofluorescence, immunohistochemical technique, and ELISA technique. The results show that the recombinant monoclonal antibody has the advantages of strong specificity, high sensitivity, strong stability, independence on animal production, suitability for quantitative production and the like, and provides an effective tool for taking the over-expressed REG gamma protein as a target for diagnosis and treatment of diseases.
Lupus nephritis (LN), a major complication in individuals diagnosed with systemic lupus erythematosus, substantially increases morbidity and mortality. Despite marked improvements in the survival of patients with severe LN over the past 50 years, complete clinical remission after immunosuppressive therapy is achieved in only half of the patients. Therefore, timely detection of LN is vital for initiating prompt therapeutic interventions and improving patient outcomes. Biomarkers have emerged as valuable tools for LN detection and monitoring; however, the complex role of these biomarkers in LN pathogenesis remains unclear. Renal biopsy remains the gold standard for the identification of the histological phenotypes of LN and guides disease management. However, the molecular pathophysiology of specific renal lesions remains poorly understood. In this review, we provide a critical, up-to-date overview of the latest developments in the field of LN biomarkers.
The control group will receive individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese) in SOPCs. A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs. The subjects in this group will receive the same schedule of follow-ups as in the intervention group, but they will not receive any follow-up booster intervention.
This group (Hydralazine;Group B) received intravenous Hydralazine and served control. Bolus doses of 5 mg administered over 2 minutes, at 20 minutes interval. Pulse and blood pressure were checked every 10 minutes interval. If SBP threshold of 160 mm Hg or DBP 110 mm Hg was still reached after 20 minutes, then second bolus was repeated. Similarly if after 20 minutes SBP was still ≥160 or DBP ≥110 mm Hg, then third dose was given. If SBP or DBP thresholds were still exceeded after 20 minutes then similarly 4th and 5th dose of 5 mg were given. Failure to reduce SBP\<160 or DBP\<110 after consecutive maximum 5 boluses(total 25 mg) was labeled as severe persistent hypertension.
PURPOSE:A pharmaceutical system releasing a physiologically active substance slowly into living body when embedded in the body, and obtained by preparing microorganisms capable of producing the physiologically active substance, and including and immobilizing the microorganisms with a urethane resin. CONSTITUTION:Cultured liquid of microorganisms capable of producing a physiologically active substance (e.g. antibiotic, enzyme, hormone, antibody, carcinostatic agent, etc.) (e.g. various actinomycetes capable of producing antibiotic substances such as streptomycin; e.g. Streptomyces griseus) or animal cells (e.g. various animal cells capable of producing lymphokine, interferon, etc. or human lymphoblastoid cell) is mixed with a urethane resin (e.g. polyurethane), and formed and hardened in a form suitable for the object to effect the inclusion and immobilization of the microorganisms, etc. with the resin. The immobilized microbial cells or animal cells are embedded in the living body of an animal (e.g. dog, cat, mouse, etc.). The immune reaction caused by the intrusion of nonself cell in the body can be prevented, and the physiologically active substance can be released continuously into the body.
Intervention Group includes 25 children and their caregivers. interventional content with educational-practical and care-support model is in the form of an audio-visual file or an educational text (5-10 minutes) within a period of three months and through the content link (Send Big website) to the email address or number. It will be sent to teenager or caregiver of children with Cystic fibrosis, and after observation, remote follow-up will be done twice a week on the Skype platform, and the researcher will answer All of the questions that relate to contents. The content included topics related to various aspects of the disease and its management, Adjusting and moderating the physical activity program, medication regimen, Nutrition, and mental health.
PURPOSE:To obtain the new subject derivative useful as a therapeutic agent for cerebral apoplexy, cerebral hemorrhage, cerebral infarct, etc., protecting brain cells during ischemia in the brain, suppressing ischemic encephalopathy by reacting a carbazole with triphosgene and treating the reaction product with an amine. CONSTITUTION:Pyridine is added to a methylene chloride suspension of a carbazole of formula I [R1 to R8 are H, lower alkyl, (substituted) lower alkoxy, OH, acetoxyl, nitro, amino, halogen, etc.] (e.g. carbazole), the carbazole is reacted with triphosgene for 4 hours to give 9-chlorocarbonylcarbazole. The reaction mixture is reacted without isolation with ammonia or an amine of the formula R9H [R9 is group of formula II (R10 is H or lower alkyl; R11 is lower alkylamino, piperidino, etc.; n is 2-4) or formula III (R12 is H or lower alkyl; m is 2 or 3) or NH2] in the presence of a base to give the objective carbazole derivative of formula IV suppressing ischemic encephalopathy.
BACKGROUND: Endoscopic submucosal dissection (ESD) is a minimally invasive resection technique that enables the en bloc resection of gastrointestinal lesions. Despite en bloc resection, pathological evaluation of lesions can reveal positive vertical or horizontal margins, which is referred to as R1 resection. Not all R1 lesions referred for surgical resection or endoscopic surveillance show evidence of residual tumor. We aimed to identify the predictors of residual neoplasia in patients with an R1 resection following ESD.
PATIENTS AND METHODS: All lesions resected via ESD between June 2016 and September 2021 at a tertiary referral center were retrospectively identified. Lesions with an R1 resection and adequate follow-up were eligible for inclusion. Patient, lesion, and procedural characteristics were analyzed to identify predictors of residual neoplasia.
RESULTS: Of 614 lesions, 163 (28%) had R1 resection. Of these, 56 lesions in 51 patients had complete follow-up and were included. Thirteen patients (25.5%) underwent surgical resection and the remainder underwent endoscopic surveillance. Seven (12.5%) patients had residual disease. All patients with residual disease had esophageal carcinoma. Positive deep and lateral margins, severe submucosal fibrosis, and moderate/poorly differentiated tumors were identified as significant predictors of residual neoplasia.
CONCLUSION: Most R1 lesions (87.5%) resected by ESD did not have residual disease on follow-up. Those without identified risk factors for residual disease, such as esophageal carcinoma, severe submucosal fibrosis, or both histological margin positivity, may benefit from a strategy of close endoscopic surveillance rather than referral for surgical resection.
Study duration for each subject is approximately 15 weeks (105 days) for Screening including patch testing, Treatment, and the initial 30-day post-treatment periods. Approximately 6 weeks after treatment, subjects will receive a second patch test. In addition, each subject will be followed from T1 for 6 months by monthly telephone follow-up to monitor adverse events. Subjects in Cohorts 2, 3 and 4 and, if applicable, additional cohorts, will not be dosed until all subjects from the prior cohort have completed the assessments after IP dosing and the Safety Review Committee has reviewed the results prior to Day T14. All subjects will be followed for 6 months after IP dosing for safety assessments, which will be carried out at monthly intervals via telephone.
INTRODUCTION: Isolated sphenoidal sinusitis (ISS) is a rare disease with non-specific symptoms and a potential for complications. Diagnosis is made clinically, endoscopically, and with imaging like CT scans or MRIs. This study aimed to evaluate if ISS meets the EPOS 2020 criteria for diagnosing acute rhinosinusitis and if new diagnostic criteria are needed.
MATERIALS AND METHODS: The study analyzed 193 charts and examination records from 2000 to 2022 in patients diagnosed with isolated sphenoidal sinusitis at the Ziv Medical Center in Safed, Israel. Of the 193, 57 patients were excluded, and the remaining 136 patients were included in the final analysis. Patients were evaluated using Ear, Nose and Throat (ENT), neurological and sinonasal video endoscopy, radiological findings, demographic data, symptoms and signs, and laboratory results. All these findings were reviewed according to the EPOS 2020 acute sinusitis diagnosis criteria and were analyzed to determine if ISS symptoms and signs fulfilled them.
RESULTS: The patients included 40 men and 96 women, ranging in age from 17 to 86 years (mean ± SD, 37 ± 15.2 years). A positive endoscopy and radiography were encountered in 29.4%, and headache was present in 98%; the most common type was retro-orbital headache (31%). The results showed that there is no relationship between the symptoms of isolated sphenoidal sinusitis and the criteria for diagnosing acute sinusitis according to EPOS 2020.
CONCLUSION: ISS is an uncommon entity encountered in clinical practice with non-specific symptoms and a potential for complications. Therefore, the condition must be kept in mind by clinicians, and prompt diagnosis and treatment must be initiated. This kind of sinusitis does not fulfill the standard guidelines for acute sinusitis diagnosis criteria.
This invention provides novel bicyclonucleoside analogues which exhibit anti-AIDS activity and intermediates to produce oligonucleotide analogues which have anti-sense or anti-gene activity as well as in vivo stability. The present invention is compounds of the following formula (1) or their pharmaceutically acceptable salts. (see formula I) R1 represents a hydrogen atom or protecting group for a hydroxy group, R2 represents an azido group or an optionally protected amino group or the like, B represents a purin-9-yl or a 2-oxo-1,2-dihydropyrimidin-1-yl group which are optionally substituted with substituents selected from .alpha. group shown below. (.alpha. group) halogen atom, alkyl group having 1-6 carbon atoms, hydroxy group, mercapto group, amino group, and the like.
Participants in guided ICBT will receive internet-delivered CBT with therapist support. The treatment consists of 8 online modules with interactive features such as videos and illustrations, delivered over a maximum of 10 weeks. The main treatment focus is behavioral activation. The adolescent and the caregiver are provided with their own separate programs and login to the treatment platform. The caregiver's program also consists of 8 chapters, including psychoeducation about depression and how to support their adolescent in treatment. The adolescents and caregivers have regular contact with a personal assigned therapist via written text messages in the platform. Participants are typically in contact with their therapist several times a week. The adolescent and caregiver can continue to access all treatment modules for the whole follow-up period (3 months), but without therapist-support.
Long term treatment with levodopa, the gold standard treatment of Parkinson's disease (PD), can lead to the development of abnormal involuntary movements called levodopa induced dyskinesia (LID). The severity of LID can range from mild to severely debilitating. A majority of PD patients will develop LID in their treatment life-time. In a recent study of the MPTP monkey model of PD, statin use was found to reduce LID (45%) without a worsening of Parkinsonism symptoms1. Another study showed rats treated with lovastatin prior to and with initiation of levodopa after substantia nigra lesioning showed dramatically less LID evolution compared to animals without lovastatin exposure2. In this study, the investigators will examine the association of statin use and dyskinesia in a convenience sample Parkinson's disease patients in the Veterans Administration Health Care System. This study is a retrospective three cohort design and will compare statin exposure BEFORE beginning LD, versus statin exposure AFTER LD is begun, versus NO statin exposure in PD subjects controlling for disease characteristics (severity), gender, and total LD exposure The primary endpoint is the severity of LID between the groups after years of opportunity to develop LID. Levodopa-Induced dyskinesia is a major cause of reduced quality of life for Veterans with PD and, in some cases, leads to costly surgical interventions. This project examines the impact of statin use on the presence of LID, and could lead to a future intervention trial. The reduction, delayed onset, or elimination of LID could improve the quality of life of many Veterans nationwide.
Participants are given LAIV4/ FluMist® and participate for single year. NP swabs are collected; no blood samples will be collected for this group. For children requiring 2 doses of vaccine, a second immunization will be given at least 28 days after Dose 1.